5) Scheibenbogen said they have funding for the plasma/CD38 study through private funding and a foundation. Sanofi owns the medication they want to trial (so the drug is probably Isatuximab = Sarclisa) and they are interested in testing it further with them.
September 25, 2025 at 3:01 PM
5) Scheibenbogen said they have funding for the plasma/CD38 study through private funding and a foundation. Sanofi owns the medication they want to trial (so the drug is probably Isatuximab = Sarclisa) and they are interested in testing it further with them.
Our brave new world of “quad-eligible” vs “quad-ineligible” in newly diagnosed myeloma regardless of ASCT is here 👏
Plus isa in 1st line as CD38 mAb… great news for #MMsm pts and congrats to IMROZ team! (And BENEFIT, IsKia, GMMG CONCEPT, & more!)
www.fda.gov/drugs/resour...
Plus isa in 1st line as CD38 mAb… great news for #MMsm pts and congrats to IMROZ team! (And BENEFIT, IsKia, GMMG CONCEPT, & more!)
www.fda.gov/drugs/resour...
FDA approves Sarclisa with bortezomib, lenalidomide, and dexamethasone
FDA approved isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC) with bortezomib, lenalidomide, and dexamethasone for adults with diagnosed multiple myeloma
www.fda.gov
September 21, 2024 at 3:10 AM
Our brave new world of “quad-eligible” vs “quad-ineligible” in newly diagnosed myeloma regardless of ASCT is here 👏
Plus isa in 1st line as CD38 mAb… great news for #MMsm pts and congrats to IMROZ team! (And BENEFIT, IsKia, GMMG CONCEPT, & more!)
www.fda.gov/drugs/resour...
Plus isa in 1st line as CD38 mAb… great news for #MMsm pts and congrats to IMROZ team! (And BENEFIT, IsKia, GMMG CONCEPT, & more!)
www.fda.gov/drugs/resour...
The #MyelomaMinute is out! Read and subscribe.
This week we feature newly published evidence-based guidelines from EHA and EMN for diagnosis, treatment, and follow-up of patients with #myeloma, EU approves Sarclisa, and upcoming events.
my.myeloma.org/webmail/1077...
#mmsm
This week we feature newly published evidence-based guidelines from EHA and EMN for diagnosis, treatment, and follow-up of patients with #myeloma, EU approves Sarclisa, and upcoming events.
my.myeloma.org/webmail/1077...
#mmsm
August 2, 2025 at 1:48 PM
The #MyelomaMinute is out! Read and subscribe.
This week we feature newly published evidence-based guidelines from EHA and EMN for diagnosis, treatment, and follow-up of patients with #myeloma, EU approves Sarclisa, and upcoming events.
my.myeloma.org/webmail/1077...
#mmsm
This week we feature newly published evidence-based guidelines from EHA and EMN for diagnosis, treatment, and follow-up of patients with #myeloma, EU approves Sarclisa, and upcoming events.
my.myeloma.org/webmail/1077...
#mmsm
🟣 Farmacêutica francesa Sanofi anunciou que recebeu aprovação da Comissão Europeia para a versão subcutânea do tratamento contra o câncer Sarclisa.
Saiba mais 👇
www.otempo.com.br/saude-e-bem-...
Saiba mais 👇
www.otempo.com.br/saude-e-bem-...
Aprovado tratamento inédito contra câncer com injetor portátil
Saiba mais sobre o tratamento pioneiro contra câncer com injetor portátil aprovado na UE, oferecendo maior comodidade e alívio aos sistemas de saúde. Leia mais.
www.otempo.com.br
June 8, 2026 at 6:57 PM
🟣 Farmacêutica francesa Sanofi anunciou que recebeu aprovação da Comissão Europeia para a versão subcutânea do tratamento contra o câncer Sarclisa.
Saiba mais 👇
www.otempo.com.br/saude-e-bem-...
Saiba mais 👇
www.otempo.com.br/saude-e-bem-...
The U.S. Food and Drug Administration said on Friday it has approved a wearable form of Sanofi's blood cancer drug, Sarclisa, offering multiple myeloma patients a less burdensome alternative to intravenous infusions.
US FDA approves Sanofi's wearable injector form of blood cancer drug
The U.S. Food and Drug Administration said on Friday it has approved a wearable form of Sanofi's blood cancer drug, Sarclisa, offering multiple myeloma patients a less burdensome alternative to intravenous infusions.
reut.rs
July 10, 2026 at 4:25 PM
The U.S. Food and Drug Administration said on Friday it has approved a wearable form of Sanofi's blood cancer drug, Sarclisa, offering multiple myeloma patients a less burdensome alternative to intravenous infusions.
The last day of #ASH24 reveals promising data on Darzalex delaying disease progression in high-risk smoldering myeloma, plus updates on Sarclisa-based quadruplet regimens for newly diagnosed #myeloma. Read the highlights from day 3 here: themmrf.org/mmrf-blogs/m...
MMRF ASH 2024 Blog: Day 3 - MMRF
Welcome to our final recap of the latest research on myeloma treatments presented at the American Society of Hematology (ASH) Annual Meeting in San Diego. Highlights from the final day included: Promi...
themmrf.org
December 12, 2024 at 7:44 PM
The last day of #ASH24 reveals promising data on Darzalex delaying disease progression in high-risk smoldering myeloma, plus updates on Sarclisa-based quadruplet regimens for newly diagnosed #myeloma. Read the highlights from day 3 here: themmrf.org/mmrf-blogs/m...
SARCLISA (isatuximab) is being studied with an on-body injector that delivers the drug subcutaneously over 12-15 minutes—no IV needed. A promising new way to make treatment more convenient! #AskTheIMF
August 23, 2025 at 2:25 PM
SARCLISA (isatuximab) is being studied with an on-body injector that delivers the drug subcutaneously over 12-15 minutes—no IV needed. A promising new way to make treatment more convenient! #AskTheIMF
Sanofi's Sarclisa Gets Approval in Europe for Multiple Myeloma 💊
July 25, 2025 at 5:06 AM
Sanofi's Sarclisa Gets Approval in Europe for Multiple Myeloma 💊
Ce que va changer ce nouveau traitement contre le cancer, approuvé par l’UE pour la première fois
Ce que va changer le traitement contre le cancer Sarclisa, approuvé par l’UE pour la première fois
www.huffingtonpost.fr
June 8, 2026 at 8:25 AM
Ce que va changer ce nouveau traitement contre le cancer, approuvé par l’UE pour la première fois
Sarclisa would be a lovely name for a little girl
January 29, 2025 at 2:36 PM
Sarclisa would be a lovely name for a little girl
The EU has approved Sanofi's Sarclisa (isatuximab) with VRd (bortezomib, lenalidomide, dexamethasone) for newly diagnosed multiple myeloma (MM) patients ineligible for stem cell transplants.
A significant step in first-line MM treatment!
#MultipleMyeloma #Oncology
A significant step in first-line MM treatment!
#MultipleMyeloma #Oncology
FirstWord
firstwordpharma.com
January 23, 2025 at 5:40 PM
The EU has approved Sanofi's Sarclisa (isatuximab) with VRd (bortezomib, lenalidomide, dexamethasone) for newly diagnosed multiple myeloma (MM) patients ineligible for stem cell transplants.
A significant step in first-line MM treatment!
#MultipleMyeloma #Oncology
A significant step in first-line MM treatment!
#MultipleMyeloma #Oncology
Dr. Jesus Berdeja provides expert insights into the FDA's recent approval of Sarclisa’s new indication for newly diagnosed #myeloma patients ineligible for stem cell transplant. In this video, learn how this impacts treatment protocols & patient care: youtu.be/zbArwwRI2Fc
New Indication for Sarclisa in Myeloma: What HCPs Need to Know – Dr. Jesus Berdeja
YouTube video by Multiple Myeloma Research Foundation - MMRF
youtu.be
February 6, 2025 at 7:06 PM
Dr. Jesus Berdeja provides expert insights into the FDA's recent approval of Sarclisa’s new indication for newly diagnosed #myeloma patients ineligible for stem cell transplant. In this video, learn how this impacts treatment protocols & patient care: youtu.be/zbArwwRI2Fc
The #FDA has extended its review of a new #subcutaneous formulation of #Sanofi's #multiple ]myeloma therapy #Sarclisa – which has long played second fiddle to Johnson & Johnson's blockbuster rival Darzalex – by three months.
pharmaphorum.com/news/fda-del...
pharmaphorum.com/news/fda-del...
FDA delays decision on Sanofi's subcutaneous Sarclisa
The FDA has extended its review of a new version of Sanofi's multiple myeloma Sarclisa that could help narrow the gap with arch-rival Darzalex.
pharmaphorum.com
April 22, 2026 at 1:21 PM
The #FDA has extended its review of a new #subcutaneous formulation of #Sanofi's #multiple ]myeloma therapy #Sarclisa – which has long played second fiddle to Johnson & Johnson's blockbuster rival Darzalex – by three months.
pharmaphorum.com/news/fda-del...
pharmaphorum.com/news/fda-del...
Can a new on-body injector version of Sanofi's Sarclisa, presented at #ASCO25, help it claim market share from J&J's rival top-selling Darzalex in multiple myeloma?
pharmaphorum.com/news/asco-25...
pharmaphorum.com/news/asco-25...
ASCO 25: Sanofi hopes on-body delivery will boost Sarclisa
Can a new on-body injector version of Sanofi's Sarclisa help it claim market share from J&J's rival top-selling Darzalex in multiple myeloma
pharmaphorum.com
June 4, 2025 at 11:40 AM
Can a new on-body injector version of Sanofi's Sarclisa, presented at #ASCO25, help it claim market share from J&J's rival top-selling Darzalex in multiple myeloma?
pharmaphorum.com/news/asco-25...
pharmaphorum.com/news/asco-25...
Dr. Tiffany Richards explains the FDA's recent approval of Sarclisa’s new indication for newly diagnosed #myeloma patients who aren't eligible for stem cell transplants. In this video, learn how this treatment offers new hope: youtu.be/Z3eGwJIHGIQ
Dr. Tiffany Richards Explains a New Indication for Sarclisa in Newly Diagnosed Myeloma Patients
YouTube video by Multiple Myeloma Research Foundation - MMRF
youtu.be
January 30, 2025 at 5:59 PM
Dr. Tiffany Richards explains the FDA's recent approval of Sarclisa’s new indication for newly diagnosed #myeloma patients who aren't eligible for stem cell transplants. In this video, learn how this treatment offers new hope: youtu.be/Z3eGwJIHGIQ
💫 #ONCOnews💫
🚨BREAKING: EU approves Sanofi’s Sarclisa (Isatuximab) for transplant-eligible newly diagnosed multiple myeloma!
✅ Backed by Phase 3 GMMG-HD7 trial showing significant MRD negativity & prolonged PFS with Sarclisa + VRd
🔗 bit.ly/ONCOnews28JU-1
#OncoAlert #OncEd #MultipleMyeloma
🚨BREAKING: EU approves Sanofi’s Sarclisa (Isatuximab) for transplant-eligible newly diagnosed multiple myeloma!
✅ Backed by Phase 3 GMMG-HD7 trial showing significant MRD negativity & prolonged PFS with Sarclisa + VRd
🔗 bit.ly/ONCOnews28JU-1
#OncoAlert #OncEd #MultipleMyeloma
July 28, 2025 at 11:31 AM
💫 #ONCOnews💫
🚨BREAKING: EU approves Sanofi’s Sarclisa (Isatuximab) for transplant-eligible newly diagnosed multiple myeloma!
✅ Backed by Phase 3 GMMG-HD7 trial showing significant MRD negativity & prolonged PFS with Sarclisa + VRd
🔗 bit.ly/ONCOnews28JU-1
#OncoAlert #OncEd #MultipleMyeloma
🚨BREAKING: EU approves Sanofi’s Sarclisa (Isatuximab) for transplant-eligible newly diagnosed multiple myeloma!
✅ Backed by Phase 3 GMMG-HD7 trial showing significant MRD negativity & prolonged PFS with Sarclisa + VRd
🔗 bit.ly/ONCOnews28JU-1
#OncoAlert #OncEd #MultipleMyeloma
I'm working on a thing with drug names:
Elahere
Libtayo
Darzalex Faspro
Imfinzi
Empliciti
Padcev
Poteligeo
Sarclisa
Yervoy
Elahere
Libtayo
Darzalex Faspro
Imfinzi
Empliciti
Padcev
Poteligeo
Sarclisa
Yervoy
January 29, 2025 at 2:35 PM
I'm working on a thing with drug names:
Elahere
Libtayo
Darzalex Faspro
Imfinzi
Empliciti
Padcev
Poteligeo
Sarclisa
Yervoy
Elahere
Libtayo
Darzalex Faspro
Imfinzi
Empliciti
Padcev
Poteligeo
Sarclisa
Yervoy
#Sanofi's subcutaneous formulation of #multiplemyeloma drug #Sarclisa has been approved in the #UK, which will be the first market for the on-body injector (#OBI) version of the drug.
buff.ly/aU3GPJd
buff.ly/aU3GPJd
June 18, 2026 at 2:00 PM
#Sanofi's subcutaneous formulation of #multiplemyeloma drug #Sarclisa has been approved in the #UK, which will be the first market for the on-body injector (#OBI) version of the drug.
buff.ly/aU3GPJd
buff.ly/aU3GPJd
Bonnes nouvelles sur le #MyélomeMultiple 🩸
Deux nouvelles thérapeutiques ont été approuvées dans l' #UE
#BLENREP ( #GSK) pour les patients atteints de #Myélome R/R
#SARCLISA ( #Sanofi) pour les patients nouvellement diagnostiqués & transplantables
myelom.online/multiples-my...
Deux nouvelles thérapeutiques ont été approuvées dans l' #UE
#BLENREP ( #GSK) pour les patients atteints de #Myélome R/R
#SARCLISA ( #Sanofi) pour les patients nouvellement diagnostiqués & transplantables
myelom.online/multiples-my...
July 26, 2025 at 8:53 AM
Bonnes nouvelles sur le #MyélomeMultiple 🩸
Deux nouvelles thérapeutiques ont été approuvées dans l' #UE
#BLENREP ( #GSK) pour les patients atteints de #Myélome R/R
#SARCLISA ( #Sanofi) pour les patients nouvellement diagnostiqués & transplantables
myelom.online/multiples-my...
Deux nouvelles thérapeutiques ont été approuvées dans l' #UE
#BLENREP ( #GSK) pour les patients atteints de #Myélome R/R
#SARCLISA ( #Sanofi) pour les patients nouvellement diagnostiqués & transplantables
myelom.online/multiples-my...
Day 2 at #ASCO25 delivered more promising updates for #myeloma patients including 5-year cancer-free results from CAR T-cell therapy, a potential new option with trispecific antibodies, a new way to give Sarclisa, and more.
Read all the highlights here: themmrf.org/mmrf-blogs/m...
Read all the highlights here: themmrf.org/mmrf-blogs/m...
MMRF at ASCO 2025: Day 1 – What Patients Should Know - MMRF
We’re excited to share highlights from the first day of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, one of the year’s most important events in cancer research. This year, res...
themmrf.org
June 4, 2025 at 9:38 PM
Day 2 at #ASCO25 delivered more promising updates for #myeloma patients including 5-year cancer-free results from CAR T-cell therapy, a potential new option with trispecific antibodies, a new way to give Sarclisa, and more.
Read all the highlights here: themmrf.org/mmrf-blogs/m...
Read all the highlights here: themmrf.org/mmrf-blogs/m...
US FDA approves Sanofi's wearable injector form of blood cancer drug 🧪https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-sanofis-wearable-injector-form-blood-cancer-drug-2026-07-10/
US FDA approves Sanofi's wearable injector form of blood cancer drug
The U.S. Food and Drug Administration said on Friday it has approved a wearable form of Sanofi's blood cancer drug, Sarclisa, offering multiple myeloma patients a less burdensome alternative to intr...
www.reuters.com
July 13, 2026 at 12:20 PM
US FDA approves Sanofi's wearable injector form of blood cancer drug 🧪https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-sanofis-wearable-injector-form-blood-cancer-drug-2026-07-10/